论文部分内容阅读
目的分析研究卡培他滨维持化疗治疗晚期胃癌和术后复发转移胃癌的临床效果。方法 42例晚期胃癌和术后复发转移胃癌患者,随机分为研究组(22例)和对照组(20例)。对照组患者化疗后采取常规治疗模式,研究组患者在对照组常规治疗基础上采取卡培他滨维持化疗,对两组患者的临床疗效和不良反应给予对比。结果研究组患者临床总有效率为68.18%,对照组为35.00%,研究组患者的治疗效果明显优于对照组,差异具有统计学意义(P<0.05)。研究组患者不良反应发生率为27.27%,对照组为55.00%,研究组患者的不良反应发生率明显低于对照组,差异具有统计学意义(P<0.05)。结论对晚期胃癌和术后复发转移胃癌患者采取卡培他滨维持化疗治疗,临床疗效可靠,不良反应较少,具有临床推广价值。
Objective To analyze the clinical effect of capecitabine in maintaining chemotherapy for advanced gastric cancer and recurrence and metastasis of gastric cancer. Methods Forty-two patients with advanced gastric cancer and recurrent and metastatic gastric cancer were randomly divided into study group (n = 22) and control group (n = 20). The patients in the control group were treated with conventional therapy after chemotherapy. The study group took capecitabine to maintain chemotherapy on the basis of routine treatment in the control group, and the clinical efficacy and adverse reactions in the two groups were compared. Results The total clinical effective rate was 68.18% in the study group and 35.00% in the control group. The treatment effect of the study group was significantly better than that of the control group (P <0.05). The incidence of adverse reactions was 27.27% in the study group and 55.00% in the control group, and the incidence of adverse reactions in the study group was significantly lower than that in the control group (P <0.05). Conclusions The use of capecitabine to maintain chemotherapy in patients with advanced gastric cancer and postoperative recurrence and metastasis of gastric cancer has reliable clinical curative effect and few adverse reactions and has clinical value of popularization.